285 related articles for article (PubMed ID: 36105316)
1. Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review.
Wong KH; Yang D; Chen S; He C; Chen M
Asian J Pharm Sci; 2022 Jul; 17(4):475-490. PubMed ID: 36105316
[TBL] [Abstract][Full Text] [Related]
2. A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin.
Yang XX; Xu X; Wang MF; Xu HZ; Peng XC; Han N; Yu TT; Li LG; Li QR; Chen X; Wen Y; Li TF
J Nanobiotechnology; 2022 May; 20(1):230. PubMed ID: 35568865
[TBL] [Abstract][Full Text] [Related]
3. MOF nanoparticles with encapsulated dihydroartemisinin as a controlled drug delivery system for enhanced cancer therapy and mechanism analysis.
Li Y; Song Y; Zhang W; Xu J; Hou J; Feng X; Zhu W
J Mater Chem B; 2020 Aug; 8(33):7382-7389. PubMed ID: 32648887
[TBL] [Abstract][Full Text] [Related]
4. Programmed Release of Dihydroartemisinin for Synergistic Cancer Therapy Using a CaCO
Wan X; Zhong H; Pan W; Li Y; Chen Y; Li N; Tang B
Angew Chem Int Ed Engl; 2019 Oct; 58(40):14134-14139. PubMed ID: 31389105
[TBL] [Abstract][Full Text] [Related]
5. Metal-organic framework-encapsulated dihydroartemisinin nanoparticles induces apoptotic cell death in ovarian cancer by blocking ROMO1-mediated ROS production.
Yan Y; Yang X; Han N; Liu Y; Liang Q; Li LG; Hu J; Li TF; Xu Z
J Nanobiotechnology; 2023 Jun; 21(1):204. PubMed ID: 37386404
[TBL] [Abstract][Full Text] [Related]
6. An Overview of Dihydroartemisinin as a Promising Lead Compound for Development of Anticancer Agents.
Olatunde OZ; Yong J; Lu C
Mini Rev Med Chem; 2023; 23(3):265-289. PubMed ID: 35469566
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin: A Potential Natural Anticancer Drug.
Dai X; Zhang X; Chen W; Chen Y; Zhang Q; Mo S; Lu J
Int J Biol Sci; 2021; 17(2):603-622. PubMed ID: 33613116
[TBL] [Abstract][Full Text] [Related]
8. Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.
Liu K; Dai L; Li C; Liu J; Wang L; Lei J
Sci Rep; 2016 Jul; 6():29461. PubMed ID: 27377918
[TBL] [Abstract][Full Text] [Related]
9. An albumin-binding dimeric prodrug nanoparticle with long blood circulation and light-triggered drug release for chemo-photodynamic combination therapy against hypoxia-induced metastasis of lung cancer.
Luo R; Zhang Z; Han L; Xue Z; Zhang K; Liu F; Feng F; Xue J; Liu W; Qu W
Biomater Sci; 2021 May; 9(10):3718-3736. PubMed ID: 34008617
[TBL] [Abstract][Full Text] [Related]
10. PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer.
Phung CD; Le TG; Nguyen VH; Vu TT; Nguyen HQ; Kim JO; Yong CS; Nguyen CN
Pharm Res; 2020 Jun; 37(7):129. PubMed ID: 32548664
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS.
Han N; Li LG; Peng XC; Ma QL; Yang ZY; Wang XY; Li J; Li QR; Yu TT; Xu HZ; Xu X; Chen X; Wang MF; Li TF
Eur J Pharmacol; 2022 Mar; 919():174797. PubMed ID: 35122867
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin-Loaded Magnetic Nanoparticles for Enhanced Chemodynamic Therapy.
Guo S; Yao X; Jiang Q; Wang K; Zhang Y; Peng H; Tang J; Yang W
Front Pharmacol; 2020; 11():226. PubMed ID: 32210814
[TBL] [Abstract][Full Text] [Related]
13. Supramolecular hybrids of carbon dots and dihydroartemisinin for enhanced anticancer activity and mechanism analysis.
Li Y; Shi N; Zhang W; Zhang H; Song Y; Zhu W; Feng X
J Mater Chem B; 2020 Nov; 8(42):9777-9784. PubMed ID: 33026041
[TBL] [Abstract][Full Text] [Related]
14. Effects of magnetic dihydroartemisinin nano-liposome in inhibiting the proliferation of head and neck squamous cell carcinomas.
Li H; Li X; Shi X; Li Z; Sun Y
Phytomedicine; 2019 Mar; 56():215-228. PubMed ID: 30668343
[TBL] [Abstract][Full Text] [Related]
15. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles.
Omwoyo WN; Melariri P; Gathirwa JW; Oloo F; Mahanga GM; Kalombo L; Ogutu B; Swai H
Nanomedicine; 2016 Apr; 12(3):801-809. PubMed ID: 26724538
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity and Molecular Mechanisms of an Ursodeoxycholic Acid Methyl Ester-Dihydroartemisinin Hybrid via a Triazole Linkage in Hepatocellular Carcinoma Cells.
Hsu YF; Kung FL; Huang TE; Deng YN; Guh JH; Marchetti P; Marchesi E; Perrone D; Navacchia ML; Hsu LC
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903603
[TBL] [Abstract][Full Text] [Related]
17. Self-assembly and self-delivery of the pure nanodrug dihydroartemisinin for tumor therapy and mechanism analysis.
Li Y; Zhang W; Shi N; Li W; Bi J; Feng X; Shi N; Zhu W; Xie Z
Biomater Sci; 2023 Mar; 11(7):2478-2485. PubMed ID: 36763165
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy.
Han W; Duan X; Ni K; Li Y; Chan C; Lin W
Biomaterials; 2022 Jan; 280():121315. PubMed ID: 34920370
[TBL] [Abstract][Full Text] [Related]
19. Dihydroartemisinin and its anticancer activity against endometrial carcinoma and cervical cancer: involvement of apoptosis, autophagy and transferrin receptor.
Tang T; Xia Q; Xi M
Singapore Med J; 2021 Feb; 62(2):96-103. PubMed ID: 31680182
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
